These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 17263189)

  • 1. Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.
    de Paulis T
    Curr Opin Investig Drugs; 2007 Jan; 8(1):78-86. PubMed ID: 17263189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
    Becker OM; Dhanoa DS; Marantz Y; Chen D; Shacham S; Cheruku S; Heifetz A; Mohanty P; Fichman M; Sharadendu A; Nudelman R; Kauffman M; Noiman S
    J Med Chem; 2006 Jun; 49(11):3116-35. PubMed ID: 16722631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
    Rickels K; Mathew S; Banov MD; Zimbroff DL; Oshana S; Parsons EC; Donahue SR; Kauffman M; Iyer GR; Reinhard JF
    J Clin Psychopharmacol; 2008 Apr; 28(2):235-9. PubMed ID: 18344738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRX-00023, a selective serotonin 1A receptor agonist, reduces ultrasonic vocalizations in infant rats bred for high infantile anxiety.
    Brunelli SA; Aviles JA; Gannon KS; Branscomb A; Shacham S
    Pharmacol Biochem Behav; 2009 Nov; 94(1):8-15. PubMed ID: 19576924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects.
    Iyer GR; Reinhard JF; Oshana S; Kauffman M; Donahue S
    J Clin Pharmacol; 2007 Jul; 47(7):817-24. PubMed ID: 17495280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.
    Mathew SJ; Garakani A; Reinhard JF; Oshana S; Donahue S
    Clin Ther; 2008 Sep; 30(9):1658-66. PubMed ID: 18840371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.
    Adell A
    IDrugs; 2010 Dec; 13(12):900-10. PubMed ID: 21154150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides.
    Fotsch C; Han N; Arasasingham P; Bo Y; Carmouche M; Chen N; Davis J; Goldberg MH; Hale C; Hsieh FY; Kelly MG; Liu Q; Norman MH; Smith DM; Stec M; Tamayo N; Xi N; Xu S; Bannon AW; Baumgartner JW
    Bioorg Med Chem Lett; 2005 Mar; 15(6):1623-7. PubMed ID: 15745810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some pharmacological properties of new analogs of MP 3022, the 5-HT1A receptor antagonist.
    Chojnacka-Wójcik E; Kłodzińska A; Tatarczyńska E; Paluchowska MH
    Pol J Pharmacol; 1999; 51(5):405-13. PubMed ID: 10817541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Novel Indolealkylpiperazine Derivatives as Potent 5-HT
    Zhu C; Li X; Peng W; Fu W
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33139658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SLV-308. Solvay.
    Wolf WA
    Curr Opin Investig Drugs; 2003 Jul; 4(7):878-82. PubMed ID: 14619412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
    Gray DL; Xu W; Campbell BM; Dounay AB; Barta N; Boroski S; Denny L; Evans L; Stratman N; Probert A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6604-7. PubMed ID: 19854053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux.
    Huang M; Horiguchi M; Felix AR; Meltzer HY
    Neuroreport; 2012 May; 23(7):436-40. PubMed ID: 22415605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a 5-HT1a receptor agonist in atopic dermatitis.
    Kawana S; Kato Y; Omi T
    Clin Exp Dermatol; 2010 Dec; 35(8):835-40. PubMed ID: 20089082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donitriptan (Pierre Fabre).
    Dukat M
    Curr Opin Investig Drugs; 2001 Mar; 2(3):415-8. PubMed ID: 11575714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-aryl-4-[(1-tetralinyl)alkyl]piperazines: alkylamido and alkylamino derivatives. Synthesis, 5-HT1A receptor affinity, and selectivity. 3.
    Perrone R; Berardi F; Leopoldo M; Tortorella V; Fornaretto MG; Caccia C; McArthur RA
    J Med Chem; 1996 Aug; 39(16):3195-202. PubMed ID: 8759642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro assessment of the agonist properties of the novel 5-HT1A receptor ligand, CUMI-101 (MMP), in rat brain tissue.
    Hendry N; Christie I; Rabiner EA; Laruelle M; Watson J
    Nucl Med Biol; 2011 Feb; 38(2):273-7. PubMed ID: 21315283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tertiary amine nitrogen atom of piperazine sulfonamides as a novel determinant of potent and selective beta3-adrenoceptor agonists.
    Perrone MG; Bleve L; Santandrea E; Vitale P; Niso M; Scilimati A
    ChemMedChem; 2009 Dec; 4(12):2080-97. PubMed ID: 19882697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities.
    Navari RM
    Curr Opin Investig Drugs; 2008 Jul; 9(7):774-85. PubMed ID: 18600583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral studies of serotonin receptor agonists as antidepressant drugs.
    Lucki I
    J Clin Psychiatry; 1991 Dec; 52 Suppl():24-31. PubMed ID: 1684363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.